To the best of our knowledge, this study represents the inaugural clinical investigation into the efficacy and safety of tocilizumab for advanced NSCLC with concomitant cachexia and elevated plasma IL‐6 levels. The gene discussed is IL6; the disease is non-small cell lung carcinoma.